Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL

Chimeric antigen receptor (CAR)-modified T-cell therapy has revolutionized the care of patients with relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL). Results from clinical trials across multiple institutions report remarkable remission rates with CD19-directed CAR-modified T-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: DiNofia, Amanda M., Maude, Shannon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745916/
https://www.ncbi.nlm.nih.gov/pubmed/31723849
http://dx.doi.org/10.1097/HS9.0000000000000279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745916/
https://www.ncbi.nlm.nih.gov/pubmed/31723849
http://dx.doi.org/10.1097/HS9.0000000000000279

Ejemplares similares